Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryo Shinnakasu

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|September 29, 2009
Enhanced Th2 cell differentiation and allergen-induced airway inflammation in Zfp35-deficient miceMasayuki Kitajima, Chiaki Iwamura, Takako Miki-Hosokawa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 12, 2012
Bcl6 controls the Th2 inflammatory activity of regulatory T cells by repressing Gata3 functionDeepali V Sawant, Sarita Sehra, Evelyn T Nguyen, et al.
International Immunology|January 16, 2026
T cell help is a limiting factor for rare anti-influenza memory B cells to reenter germinal centers and generate potent broadly neutralizing antibodiesYang Xue, Yuki Tai, Hiromi Yamamoto, et al.
Cancer Science|September 1, 2010
A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapyKohsuke Okita, Shinichiro Motohashi, Ryo Shinnakasu, et al.
Immunity|April 8, 2018
KLRG1<sup>+</sup> Effector CD8<sup>+</sup> T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective ImmunityDietmar Herndler-Brandstetter, Harumichi Ishigame, Ryo Shinnakasu, et al.
Nature Communications|August 30, 2019
Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodiesYu Adachi, Keisuke Tonouchi, Arnone Nithichanon, et al.
The Journal of Experimental Medicine|October 8, 2021
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related virusesRyo Shinnakasu, Shuhei Sakakibara, Hiromi Yamamoto, et al.
The Journal of Experimental Medicine|December 13, 2022
Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccineesTakeshi Inoue, Ryo Shinnakasu, Chie Kawai, et al.
Science Advances|June 14, 2023
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopesTaishi Onodera, Nicolas Sax, Takashi Sato, et al.
Frontiers in Immunology|March 20, 2025
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost studyMasaya Fujitani, Xiuyuan Lu, Ryo Shinnakasu, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|September 29, 2009
Enhanced Th2 cell differentiation and allergen-induced airway inflammation in Zfp35-deficient miceMasayuki Kitajima, Chiaki Iwamura, Takako Miki-Hosokawa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 12, 2012
Bcl6 controls the Th2 inflammatory activity of regulatory T cells by repressing Gata3 functionDeepali V Sawant, Sarita Sehra, Evelyn T Nguyen, et al.
International Immunology|January 16, 2026
T cell help is a limiting factor for rare anti-influenza memory B cells to reenter germinal centers and generate potent broadly neutralizing antibodiesYang Xue, Yuki Tai, Hiromi Yamamoto, et al.
Cancer Science|September 1, 2010
A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapyKohsuke Okita, Shinichiro Motohashi, Ryo Shinnakasu, et al.
Immunity|April 8, 2018
KLRG1<sup>+</sup> Effector CD8<sup>+</sup> T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective ImmunityDietmar Herndler-Brandstetter, Harumichi Ishigame, Ryo Shinnakasu, et al.
Nature Communications|August 30, 2019
Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodiesYu Adachi, Keisuke Tonouchi, Arnone Nithichanon, et al.
The Journal of Experimental Medicine|October 8, 2021
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related virusesRyo Shinnakasu, Shuhei Sakakibara, Hiromi Yamamoto, et al.
The Journal of Experimental Medicine|December 13, 2022
Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccineesTakeshi Inoue, Ryo Shinnakasu, Chie Kawai, et al.
Science Advances|June 14, 2023
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopesTaishi Onodera, Nicolas Sax, Takashi Sato, et al.
Frontiers in Immunology|March 20, 2025
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost studyMasaya Fujitani, Xiuyuan Lu, Ryo Shinnakasu, et al.
Pageof 4